| RABEPRAZOLE 20 MG + ONDANSETRON 4 MG TAB |
₹850.00
RABDRIP-OD is an advanced gastro-protective and antiemetic formulation from Floriwa Labs, designed to provide dual relief from acid-related disorders and associated nausea or vomiting. This powerful combination of Rabeprazole 20 mg and Ondansetron 4 mg ensures effective management of hyperacidity, gastroesophageal reflux disease (GERD), gastritis, and nausea linked to gastric disturbances.
RABDRIP-OD is widely prescribed by gastroenterologists and general physicians for patients suffering from persistent acidity along with vomiting sensation, making it a highly effective solution in the gastro segment.
Each tablet contains:
Rabeprazole 20 mg
Ondansetron 4 mg
Rabeprazole is a Proton Pump Inhibitor (PPI) that works by blocking the gastric proton pump, thereby reducing excess acid secretion in the stomach. It provides long-lasting acid suppression and promotes healing of acid-damaged tissues.
Ondansetron is an antiemetic agent that blocks serotonin receptors responsible for nausea and vomiting. It effectively controls vomiting caused by gastritis, acid reflux, or medication-induced gastric irritation.
RABDRIP-OD is indicated for:
Gastroesophageal Reflux Disease (GERD)
Hyperacidity
Gastritis
Peptic ulcer disease
Acid-related nausea and vomiting
Dyspepsia with vomiting sensation
✔ Dual action for acidity and nausea
✔ Rapid symptom relief
✔ Promotes ulcer healing
✔ Improves patient comfort and compliance
✔ Suitable for short-term and physician-directed therapy
As directed by the physician.
Generally recommended once daily before meals.
High-quality manufacturing standards
Effective PPI + antiemetic combination
Strong demand in gastro care segment
Trusted brand from Floriwa Labs
Ideal for PCD Pharma Franchise opportunities
Store in a cool and dry place.
Protect from moisture and direct sunlight.
Keep out of reach of children.
| Packaging | ALU ALU, 10*10 |
|---|
“Floriwa Labs stands among the best Gynae PCD pharma companies in India with a strong focus on quality, care, and partnerships.”
